Top

Published in:

01-02-2016 | Original Article

Galectin-1 is associated with poor prognosis in patients with cutaneous head and neck cancer with perineural spread

Authors: Sharad Chawla, Timothy A. Warren, Leesa F. Wockner, Duncan L. J. Lambie, Ian S. Brown, Thomas P. C. Martin, Rajiv Khanna, Graham R. Leggatt, Benedict J. Panizza

Published in: Cancer Immunology, Immunotherapy | Issue 2/2016

Abstract

Spread of head and neck cancer along the cranial nerves is often a lethal complication of this tumour. Current treatment options include surgical resection and/or radiotherapy, but recurrence is a frequent event suggesting that our understanding of this tumour and its microenvironment is incomplete. In this study, we have analysed the nature of the perineural tumour microenvironment by immunohistochemistry with particular focus on immune cells and molecules, which might impair anti-tumour immunity. Moderate to marked lymphocyte infiltrates were present in 58.8 % of the patient cohort including T cells, B cells and FoxP3-expressing T cells. While human leukocyte antigen (HLA) class I and more variably HLA class II were expressed on the tumour cells, this did not associate with patient survival or recurrence. In contrast, galectin-1 staining within lymphocyte areas of the tumour was significantly associated with a poorer patient outcome. Given the known role of galectin-1 in immune suppression, the data suggest that galectin inhibitors might improve the prognosis of patients with perineural spread of cancer.

Cakir BO, Adamson P, Cingi C (2012) Epidemiology and economic burden of nonmelanoma skin cancer. Facial Plast Surg Clin North Am 20(4):419–422. doi:10.1016/j.fsc.2012.07.004 CrossRefPubMed

Panizza B, Warren TA, Solares CA, Boyle GM, Lambie D, Brown I (2013) Histopathological features of clinical perineural invasion of cutaneous squamous cell carcinoma of the head and neck and the potential implications for treatment. Head Neck 36(11):1611–1618. doi:10.1002/hed.23509 CrossRefPubMed

Solares CA, Lee K, Parmar P, O’Rourke P, Panizza B (2012) Epidemiology of clinical perineural invasion in cutaneous squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 146(5):746–751. doi:10.1177/0194599811434897 CrossRefPubMed

Lin C, Tripcony L, Keller J, Poulsen M, Martin J, Jackson J, Dickie G (2012) Perineural infiltration of cutaneous squamous cell carcinoma and basal cell carcinoma without clinical features. Int J Radiat Oncol Biol Phys 82(1):334–340. doi:10.1016/j.ijrobp.2010.09.040 CrossRefPubMed

ten Hove MW, Glaser JS, Schatz NJ (1997) Occult perineural tumor infiltration of the trigeminal nerve. Diagnostic considerations. J Neuroophthalmol 17(3):170–177PubMed

Panizza B, Solares CA, Redmond M et al (2011) Surgical resection for clinical perineural invasion from cutaneous squamous cell carcinoma of the head and neck. Head Neck 34:1622–1627CrossRefPubMed

Mbeunkui F, Johann DJ Jr (2009) Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63(4):571–582. doi:10.1007/s00280-008-0881-9 PubMedCentralCrossRefPubMed

Schaaij-Visser TB, de Wit M, Lam SW, Jimenez CR (2013) The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim Biophys Acta 1834(11):2242–2258. doi:10.1016/j.bbapap.2013.01.029 CrossRefPubMed

Paltridge JL, Belle L, Khew-Goodall Y (2013) The secretome in cancer progression. Biochim Biophys Acta 1834(11):2233–2241. doi:10.1016/j.bbapap.2013.03.014 CrossRefPubMed

10.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S (2014) Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 40(2):307–319. doi:10.1016/j.ctrv.2013.07.007 CrossRefPubMed

11.

Cedeno-Laurent F, Dimitroff CJ (2012) Galectins and their ligands: negative regulators of anti-tumor immunity. Glycoconj J 29(8–9):619–625. doi:10.1007/s10719-012-9379-0 PubMedCentralCrossRefPubMed

12.

Viguier M, Advedissian T, Delacour D, Poirier F, Deshayes F (2014) Galectins in epithelial functions. Tissue Barriers 2:e29103. doi:10.4161/tisb.29103 PubMedCentralCrossRefPubMed

13.

Cedeno-Laurent F, Dimitroff CJ (2012) Galectin-1 research in T cell immunity: past, present and future. Clin Immunol 142(2):107–116. doi:10.1016/j.clim.2011.09.011 PubMedCentralCrossRefPubMed

14.

Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10:e17. doi:10.1017/S1462399408000719 CrossRefPubMed

15.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013 CrossRefPubMed

16.

Schlosser HA, Theurich S, Shimabukuro-Vornhagen A, Holtick U, Stippel DL, Bergwelt-Baildon M (2014) Overcoming tumor-mediated immunosuppression. Immunotherapy 6(9):973–988. doi:10.2217/imt.14.58 CrossRefPubMed

17.

Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J (2010) Natural immunity to cancer in humans. Curr Opin Immunol 22(2):215–222. doi:10.1016/j.coi.2010.02.006 CrossRefPubMed

18.

Galon J, Fridman WH, Pages F (2007) The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67(5):1883–1886. doi:10.1158/0008-5472.CAN-06-4806 CrossRefPubMed

19.

Chiang WF, Liu SY, Fang LY, Lin CN, Wu MH, Chen YC, Chen YL, Jin YT (2008) Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncol 44(4):325–334. doi:10.1016/j.oraloncology.2007.03.004 CrossRefPubMed

20.

Ding YM, Dong JH, Chen LL, Zhang HD (2009) Increased expression of galectin-1 is associated with human oral squamous cell carcinoma development. Oncol Rep 21(4):983–987PubMed

21.

Alves PM, Godoy GP, Gomes DQ, Medeiros AM, de Souza LB, da Silveira EJ, Vasconcelos MG, Queiroz LM (2011) Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue. Pathol Res Pract 207(4):236–240. doi:10.1016/j.prp.2011.02.004 CrossRefPubMed

22.

Tang CE, Tan T, Li C, Chen ZC, Ruan L, Wang HH, Su T, Zhang PF, Xiao ZQ (2010) Identification of Galectin-1 as a novel biomarker in nasopharyngeal carcinoma by proteomic analysis. Oncol Rep 24(2):495–500PubMed

23.

Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, Tornillo L, Capasso M, Tiribelli C, Iolascon A (2010) Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med 16(3–4):102–115. doi:10.2119/molmed.2009.00119 PubMedCentralPubMed

24.

Cimmino F, Schulte JH, Zollo M, Koster J, Versteeg R, Iolascon A, Eggert A, Schramm A (2009) Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. Oncogene 28(19):2015–2023. doi:10.1038/onc.2009.70 CrossRefPubMed

25.

Bacigalupo ML, Manzi M, Rabinovich GA, Troncoso MF (2013) Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J Gastroenterol 19(47):8831–8849. doi:10.3748/wjg.v19.i47.8831 PubMedCentralCrossRefPubMed

26.

Tang D, Yuan Z, Xue X, Lu Z, Zhang Y, Wang H, Chen M, An Y, Wei J, Zhu Y, Miao Y, Jiang K (2012) High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int J Cancer 130(10):2337–2348. doi:10.1002/ijc.26290 CrossRefPubMed

27.

Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5(3):241–251CrossRefPubMed

28.

Rabinovich GA, Croci DO (2012) Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 36(3):322–335. doi:10.1016/j.immuni.2012.03.004 CrossRefPubMed

29.

Kuo PL, Hung JY, Huang SK, Chou SH, Cheng DE, Jong YJ, Hung CH, Yang CJ, Tsai YM, Hsu YL, Huang MS (2011) Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol 186(3):1521–1530. doi:10.4049/jimmunol.1002940 CrossRefPubMed

30.

Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA (2007) The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 104(32):13134–13139. doi:10.1073/pnas.0706017104 PubMedCentralCrossRefPubMed

31.

Banh A, Zhang J, Cao H, Bouley DM, Kwok S, Kong C, Giaccia AJ, Koong AC, Le QT (2011) Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 71(13):4423–4431. doi:10.1158/0008-5472.CAN-10-4157 PubMedCentralCrossRefPubMed

32.

Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O’Byrne KJ, Giaccia AJ, Koong AC (2005) Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23(35):8932–8941. doi:10.1200/JCO.2005.02.0206 CrossRefPubMed

33.

van den Brule FA, Waltregny D, Castronovo V (2001) Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 193(1):80–87. doi:10.1002/1096-9896(2000)9999:9999<:AID-PATH730>3.0.CO;2-2 CrossRefPubMed

34.

Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler RI (2007) Galectin-1: a key effector of regulation mediated by CD4 + CD25 + T cells. Blood 109(5):2058–2065. doi:10.1182/blood-2006-04-016451 CrossRefPubMed

35.

Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD, Zwirner NW, Poirier F, Riley EM, Baum LG, Rabinovich GA (2007) Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8(8):825–834. doi:10.1038/ni1482 CrossRefPubMed

36.

Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29(8):1093–1102. doi:10.1038/onc.2009.416 CrossRefPubMed

37.

Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, Fumoleau P, Ghiringhelli F (2011) Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 125(1):65–72. doi:10.1007/s10549-010-0831-1 CrossRefPubMed

38.

Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS (2007) Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25(7):869–875. doi:10.1200/JCO.2006.08.9755 CrossRefPubMed

39.

Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL (2002) Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8(10):3137–3145PubMed

40.

Kyrgidis A, Tzellos TG, Kechagias N, Patrikidou A, Xirou P, Kitikidou K, Bourlidou E, Vahtsevanos K, Antoniades K (2010) Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. Eur J Cancer 46(9):1563–1572. doi:10.1016/j.ejca.2010.02.046 CrossRefPubMed

41.

Csiba A, Whitwell HL, Moore M (1984) Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonic neoplasms. Br J Cancer 50(5):699–709PubMedCentralCrossRefPubMed

42.

Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, Tampe R, Huber C (1996) Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 2(8):1427–1433PubMed

43.

Seliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F, Huber C (1996) Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56(8):1756–1760PubMed

Title: Galectin-1 is associated with poor prognosis in patients with cutaneous head and neck cancer with perineural spread
Authors: Sharad Chawla
Timothy A. Warren
Leesa F. Wockner
Duncan L. J. Lambie
Ian S. Brown
Thomas P. C. Martin
Rajiv Khanna
Graham R. Leggatt
Benedict J. Panizza
Publication date: 01-02-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 2/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-015-1788-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Neutrophil–lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy

Poly(I:C) potentiates Bacillus Calmette–Guérin immunotherapy for bladder cancer

Acknowledgement

Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients

A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer

IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer